학술논문
Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis: Post hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI).
Document Type
Academic Journal
Author
Misaki K; Department of Rheumatology, Kita-Harima Medical Center, Hyogo, Japan.; Tamura N; Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.; Azuma T; Azuma Rheumatology Clinic, Saitama, Japan.; Shinoda K; First Department of Internal Medicine, University of Toyama, Toyama, Japan.; Tanaka M; Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.; Fujiwara H; Division of Rheumatology, Osaka General Medical Center, Osaka, Japan.; Tsuboi H; Department of Orthopaedic Surgery, Osaka Rosai Hospital, Osaka, Japan.; Kasama T; Department of Rheumatology, Showa University Koto Toyosu Hospital, Tokyo, Japan.; Yoshimi R; Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.; Hanyu T; Department of Rheumatology, Nagaoka Red Cross Hospital, Niigata, Japan.; Kusaka Y; Department of Orthopaedic Surgery, Asahi University Hospital, Gifu, Japan.; Hirao M; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.; Onishi M; Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Ehime, Japan.; Uchino A; Department of Rheumatology, Aso Iizuka Hospital, Fukuoka, Japan.; Izumiyama T; Higashisendai Rheumatic Disease Clinic, Miyagi, Japan.; Yang KS; Department of Geriatric General Medicine, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University Faculty of Medicine, Tokyo, Japan.; Ogawa N; Department of Internal Medicine 3, Hamamatsu University School of Medicine, Shizuoka, Japan.; Matsui K; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.; Kurasawa K; Department of Rheumatology, Dokkyo Medical University, Tochigi, Japan.; Kawaai S; Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.; Yasuoka H; Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine, Aichi, Japan.; Okumura N; Department of Orthopaedic Surgery, Shiga University of Medical Science, Shiga, Japan.; Ueda Y; Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Hyogo, Japan.; Tanaka E; Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.; Inoue E; Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.; Showa University Research Administration Center, Showa University, Tokyo, Japan.; Tsuritani K; Department of Immunology Medical, Bristol-Myers Squibb, Tokyo, Japan.; Matsumoto S; Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan.; Yamanaka H; Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.; Department of Rheumatology, Sanno Medical Center, Tokyo, Japan.; Harigai M; Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Source
Publisher: Oxford University Press Country of Publication: England NLM ID: 100959226 Publication Model: Print Cited Medium: Internet ISSN: 1439-7609 (Electronic) Linking ISSN: 14397595 NLM ISO Abbreviation: Mod Rheumatol Subsets: MEDLINE
Subject
Language
English
Abstract
Objectives: The aim of the article is to investigate the associations of disease duration and anti-cyclic citrullinated peptide antibody (ACPA) status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis (RA).
Methods: We performed post hoc analyses of the Orencia® Registry in Geographically Assembled Multicenter Investigation (ORIGAMI) study of biologic-naïve RA patients aged ≥20 years with moderate disease activity who were prescribed abatacept. Changes in the Simplified Disease Activity Index (SDAI) and Japanese Health Assessment Questionnaire (J-HAQ) at 4, 24, and 52 weeks of treatment were analysed in patients divided according to ACPA serostatus (positive/negative), disease duration (<1/≥1 year), or both.
Results: SDAI scores decreased from baseline in all groups. SDAI scores tended to decrease more in the ACPA-positive group and disease duration <1-year group than in the ACPA-negative group and disease duration ≥1-year group, respectively. In the disease duration <1-year group, SDAI tended to decrease more in the ACPA-positive group than in the ACPA-negative group. Disease duration was independently associated with the change in SDAI and SDAI remission at Week 52 in multivariable regression models.
Conclusions: These results suggest that starting abatacept within 1 year of diagnosis was associated with greater effectiveness of abatacept in biologic-naïve patients with RA and moderate disease activity.
(© Japan College of Rheumatology 2023. Published by Oxford University Press.)
Methods: We performed post hoc analyses of the Orencia® Registry in Geographically Assembled Multicenter Investigation (ORIGAMI) study of biologic-naïve RA patients aged ≥20 years with moderate disease activity who were prescribed abatacept. Changes in the Simplified Disease Activity Index (SDAI) and Japanese Health Assessment Questionnaire (J-HAQ) at 4, 24, and 52 weeks of treatment were analysed in patients divided according to ACPA serostatus (positive/negative), disease duration (<1/≥1 year), or both.
Results: SDAI scores decreased from baseline in all groups. SDAI scores tended to decrease more in the ACPA-positive group and disease duration <1-year group than in the ACPA-negative group and disease duration ≥1-year group, respectively. In the disease duration <1-year group, SDAI tended to decrease more in the ACPA-positive group than in the ACPA-negative group. Disease duration was independently associated with the change in SDAI and SDAI remission at Week 52 in multivariable regression models.
Conclusions: These results suggest that starting abatacept within 1 year of diagnosis was associated with greater effectiveness of abatacept in biologic-naïve patients with RA and moderate disease activity.
(© Japan College of Rheumatology 2023. Published by Oxford University Press.)